Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes

Author:

Ornella Mefotse Saha Cyrelle12,Badrinath Narayanasamy2,Kim Kyeong-Ae2,Kim Jung Hee2,Cho Euna2,Hwang Tae-Ho12,Kim Jae-Joon3ORCID

Affiliation:

1. Department of Pharmacology, School of Medicine, Pusan National University, Yangsan 50612, Republic of Korea

2. Bionoxx Inc., Parkview Tower #1905, 248 Jeongjail-ro, Bundang-gu, Seongnam 13554, Republic of Korea

3. Division of Hematology & Oncology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan 50612, Republic of Korea

Abstract

Peritoneal metastasis, also known as peritoneal carcinomatosis (PC), is a refractory cancer that is typically resistant to conventional therapies. The typical treatment for PC is a combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Recently, research in this area has seen significant advances, particularly in immunotherapy as an alternative therapy for PC, which is very encouraging. Catumaxomab is a trifunctional antibody intraperitoneal (IP) immunotherapy authorized in Europe that can be used to diminish malignant ascites by targeting EpCAM. Intraperitoneal (IP) immunotherapy breaks immunological tolerance to treat peritoneal illness. Increasing T-cell responses and vaccination against tumor-associated antigens are two methods of treatment. CAR-T cells, vaccine-based therapeutics, dendritic cells (DCs) in combination with pro-inflammatory cytokines and NKs, adoptive cell transfer, and immune checkpoint inhibitors are promising treatments for PC. Carcinoembryonic antigen-expressing tumors are suppressed by IP administration of CAR-T cells. This reaction was strengthened by anti-PD-L1 or anti-Gr1. When paired with CD137 co-stimulatory signaling, CAR-T cells for folate receptor cancers made it easier for T-cell tumors to find their way to and stay alive in the body.

Funder

Research institute for Convergence of biomedical science and technology, Pusan National University Yangsan Hospital

Publisher

MDPI AG

Subject

Cancer Research,Oncology

Reference151 articles.

1. Willaims, S.C.P. (2022, July 09). Peritoneal Carcinomatosis: Cause, Symptoms, Diagnosis, and Treatment. Available online: https://www.webmd.com/cancer/what-is-peritoneal-carcinomatosis.

2. Peritoneal Carcinomatosis;Coccolini;World J. Gastroenterol.,2013

3. Peritoneal Carcinomatosis: Limits of Diagnosis and the Case for Liquid Biopsy;McMullen;Oncotarget,2017

4. Surgical Management of Bowel Obstruction in Patients with Peritoneal Carcinomatosis;Jayakrishnan;J. Surg. Oncol.,2014

5. Small Intestinal Obstruction from Peritoneal Carcinomatosis;Glass;Am. J. Surg.,1973

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3